The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.

Breast cancer patients in England and Wales will not have access to the drug after pricing negotiations failed between NICE and drugmakers.

NEW YORK – Apeiron Therapeutics on Tuesday said it enrolled the first patient with MTAP-deleted advanced cancer in a Phase Ia/b trial testing the activity of its PRMT5 inhibitor GTA182. In the ...

The firm is paying €7 million to add fibroblast activation protein-targeting assets to its pipeline, which it will initially develop for bladder cancer.

The company expects the trial to support the submission of a biologics license application with the US Food and Drug Administration in 2026.

In the trial, researchers will test how well Medera's SRD-001 gene therapy improves symptoms in heart failure patients with reduced ejection fraction.

NEW YORK – The European Commission (EC) on Monday granted marketing authorization to AbbVie's Elahere (mirvetuximab soravtansine) as a new therapy option for previously treated patients with folate ...

If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.

Following this update, the company's stock price dropped more than 30 percent from market close Friday to $23.79 per share Monday morning.

The firm is now inking revenue-generating contracts with other biotech companies for its drug response prediction and gene expression analysis capabilities.

NEW YORK – AstraZeneca has selected an autologous T-regulator (Treg) cell therapy candidate from Quell Therapeutics' pipeline to advance into preclinical and clinical trials in type 1 diabetes, ...

Eight NHS cancer centers will examine tumors from patients with exceptional survival times, focusing on three aggressive cancer types.